Ignite Creation Date:
2024-05-05 @ 11:19 PM
Last Modification Date:
2024-10-26 @ 10:32 AM
Study NCT ID:
NCT01307592
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2011-03-01
Brief Title:
Gemcitabine Hydrochloride Rituximab Oxaliplatin and Lenalidomide in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma
Sponsor:
Organization:
National Cancer Institute NCI
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
70
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: